Implant treatment method and implant treatment machine

Abstract

The implant processing method disclosed in this application includes the following steps: centrifuging blood from a blood collection tube to obtain liquid autologous platelet aggregate, extracting liquid autologous concentrated growth factor from it, and injecting the liquid autologous concentrated growth factor into a liquid autologous concentrated growth factor container; placing an untreated implant into the liquid autologous concentrated growth factor container to immerse it in the liquid autologous concentrated growth factor; and centrifuging the liquid autologous concentrated growth factor and the untreated implant to obtain an implant with its surface covered by the patient's autologous concentrated growth factor, which serves as a surface-treated implant to be implanted in the patient's oral cavity. This application can provide personalized implant processing solutions based on individual patient characteristics, effectively enhancing the integration ability of the implant with bone tissue, promoting new bone formation, and thus improving the implantation outcome.

Description

Technical Field

[0001] This application relates to medical material processing technology, specifically to implant processing methods and implant processing machines. Background Technology

[0002] In the field of dental implant technology, various standardized surface treatment methods are currently used clinically to improve the osseointegration of implants. However, due to individual differences among patients, implants with uniform surface characteristics are difficult to adapt to the physiological conditions of all patients. This leads to some patients still experiencing slow implant-bone integration and prolonged postoperative healing periods, affecting the implantation outcome. Therefore, how to improve the osseointegration of implants remains a problem that needs to be solved clinically. Summary of the Invention

[0003] The implant processing method and implant processing machine provided in this application are used to improve the osseointegration capacity of implants.

[0004] This application provides a method for implant processing, comprising: centrifuging blood in a blood collection tube to obtain a liquid autologous platelet aggregate, wherein the blood in the blood collection tube is the blood of a patient to be implanted in the oral cavity; extracting liquid autologous concentrated growth factor from the liquid autologous platelet aggregate and injecting the liquid autologous concentrated growth factor into a liquid autologous concentrated growth factor container; placing an untreated implant into the liquid autologous concentrated growth factor container so that the untreated implant is immersed in the liquid autologous concentrated growth factor, wherein the untreated implant is an implant not covered with the patient's autologous concentrated growth factor; centrifuging the liquid autologous concentrated growth factor and the untreated implant to obtain an implant with the patient's autologous concentrated growth factor on its surface, which is then used as a surface-treated implant to be implanted in the patient's oral cavity.

[0005] This application provides an implant processing machine, including: a blood collection tube inlet mechanism, a first centrifuge, a liquid autologous growth factor extractor, a second centrifuge, an implant inlet mechanism, and an implant outlet mechanism; the blood collection tube inlet mechanism is used to place a blood collection tube to be inserted into the implant processing machine and to send the blood collection tube to the first centrifuge, the blood collection tube carrying blood from a patient to be implanted in the oral cavity; the first centrifuge is used to centrifuge the blood in the blood collection tube to obtain liquid autologous platelet aggregate, and to send the blood collection tube carrying the liquid autologous platelet aggregate to the liquid autologous growth factor extractor; the liquid autologous growth factor extractor is used to extract liquid autologous growth factor from the liquid autologous platelet aggregate carried by the blood collection tube, inject the liquid autologous growth factor into a liquid autologous growth factor container, and then... A container of liquid autologous concentrated growth factor is sent to the second centrifuge; the implant inlet mechanism is used to place an implant that is not covered with the patient's autologous concentrated growth factor, and the implant that is not covered with the patient's autologous concentrated growth factor is used as an untreated implant; the untreated implant is sent to the second centrifuge; the second centrifuge is used to place the untreated implant into the container of liquid autologous concentrated growth factor, so that the untreated implant is immersed in the liquid autologous concentrated growth factor, and to centrifuge the liquid autologous concentrated growth factor and the untreated implant to obtain an implant with the patient's autologous concentrated growth factor on its surface, which is used as a post-treated implant, and the post-treated implant is sent to the implant outlet mechanism; the implant outlet mechanism is used to place the post-treated implant to be implanted in the patient's oral cavity.

[0006] Compared with the prior art, the embodiments of this application have the following advantages: The implant processing method and machine provided in this application embodiment include the following steps: centrifuging blood in a blood collection tube to obtain liquid autologous platelet agglomerate, wherein the blood in the blood collection tube is the blood of the patient to be implanted in the oral cavity; extracting liquid autologous concentrated growth factor from the liquid autologous platelet agglomerate and injecting the liquid autologous concentrated growth factor into a liquid autologous concentrated growth factor container; placing the untreated implant into the liquid autologous concentrated growth factor container so that the untreated implant is immersed in the liquid autologous concentrated growth factor; centrifuging the liquid autologous concentrated growth factor and the untreated implant to obtain an implant with the surface covered with the patient's autologous concentrated growth factor, which serves as the surface-treated implant to be implanted in the patient's oral cavity. In this application embodiment, by combining the individual characteristics of the patient and using the patient's liquid autologous concentrated growth factor to treat the surface of the implant, a personalized implant surface treatment plan is provided for patients with different physiological conditions, effectively enhancing the integration ability of the implant with bone tissue, thereby improving the implantation effect. Attached Figure Description

[0007] Figure 1 This is a schematic diagram of the implant processing machine provided in the embodiments of this application.

[0008] Figure 2 These are schematic diagrams of blood to be centrifuged and liquid autologous platelet aggregates provided in the embodiments of this application.

[0009] Figure 3A This is a partial (before centrifugation) structural schematic diagram of the first centrifuge provided in the embodiments of this application.

[0010] Figure 3B This is a partial (after centrifugation) structural schematic diagram of the first centrifuge provided in the embodiments of this application.

[0011] Figure 4 This is a partial structural schematic diagram of the second centrifuge provided in an embodiment of this application.

[0012] Figure 5 This is a flowchart of the implant processing method provided in the embodiments of this application. Detailed Implementation

[0013] Many specific details are set forth in the following description to provide a full understanding of this application. However, this application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of this application; therefore, this application is not limited to the specific embodiments disclosed below.

[0014] The first embodiment of this application provides an implant processing machine 100, such as... Figure 1As shown, it includes: a blood collection tube inlet mechanism 101, a first centrifuge 102, a liquid autologous concentrated growth factor extractor 103, a second centrifuge 109, an implant inlet mechanism 105, an implant outlet mechanism 110, and a controller 111.

[0015] Specifically, the implant processor 100 is equipped with a blood collection tube inlet mechanism 101 for placing blood collection tubes 114 to be inserted into the implant processor 100 and sending the blood collection tubes to the first centrifuge 102. The blood collection tubes 114 contain the patient's blood for implantation in the oral cavity. The implant processor 100 is also equipped with an implant inlet mechanism 105 for placing untreated implants 115 that are not covered with the patient's autologous concentrated growth factor. Implants without the patient's autologous concentrated growth factor are designated as untreated implants 115. The blood collection tube inlet mechanism 101 and the implant inlet mechanism 105 can be configured as pop-out drawer structures, with corresponding clamping components adapted to the specifications of the blood collection tubes 114 or implants 115 inside. Medical personnel can press the pop-out button to pop out the drawer-type inlet mechanism, insert the blood collection tube 114 or implant 115, and the clamping components can fix it to prevent displacement; then, pushing the drawer closes the inlet mechanism, thus completing the placement of the blood collection tube 114 or implant 115.

[0016] In practice, medical staff first draw the patient's venous blood into a dedicated blood collection tube 114, which will be used as the patient's autologous blood for subsequent processing of the implant 115 to be placed in the patient's oral cavity. Then, the medical staff place the blood collection tube 114 containing the patient's blood into the blood collection tube inlet mechanism 101. The blood collection tube inlet mechanism 101 can be equipped with a barcode scanner to automatically scan the identification code (such as the patient information barcode or blood collection tube specification code) on the outer wall of the blood collection tube 114 and send the scanned information to the controller 111 for verification in real time.

[0017] If the controller 111 confirms that the scan information matches the patient's medical information (such as name and ID number), the implant processor 100 will start the subsequent processing procedure; if the information does not match (such as the blood collection tube scan information does not match the patient information), the controller 111 will trigger the shutdown protection mechanism, and the processor 100 will not perform subsequent operations until medical staff check and correct the information error.

[0018] It should be noted that the blood collection tube 114 is a disposable blood collection tube. The implant processing machine 100 can also be equipped with a waste outlet. After the liquid autologous concentrated growth factor extractor 103 completes the extraction of liquid autologous concentrated growth factor in the blood collection tube 114, the controller 111 will drive the conveying mechanism to convey the blood collection tube 114 to the waste outlet.

[0019] The first centrifuge 102 is used to centrifuge the blood in the blood collection tube 114 to obtain liquid autologous platelet agglomerate. The blood collection tube 114 containing the liquid autologous platelet agglomerate is then sent to the liquid autologous concentrated growth factor extractor 103. Specifically, the centrifugation of the blood in the blood collection tube 114 can be performed according to a multi-stage speed program. For example, first, acceleration is completed within 30 seconds to reach a speed of 2700 rpm; then, multi-stage uniform centrifugation is performed, successively at 2700 rpm for 2 minutes, 2400 rpm for 4 minutes, 2700 rpm for 4 minutes, and finally at 3000 rpm for 3 minutes. After uniform centrifugation, the centrifuge gradually decelerates until it stops completely within 36 seconds. For the speed and time parameters used in CGF preparation in this application, please refer to the relevant parameter settings disclosed in the CGF preparation section of "Biological Characterization and In Vitro Effects of Human Concentrated Growth Factor Preparation: An Innovative Approach to Tissue Regeneration".

[0020] This is illustrative; please refer to it. Figure 2 The diagram 200 shows the blood to be centrifuged. After the centrifugation process is completed, the blood collection tube 114 containing the processed blood is allowed to stand, yielding liquid autologous platelet agglomerate. It should be noted that the blood will separate into layers after centrifugation, with each layer showing distinct differences in color and texture. The following are typical characteristics of each layer for reference. Figure 2The upper layer is platelet-poor plasma (PPP) 201, which is pale yellow or transparent and has a clear, thin texture. Its main component is plasma. The middle layer is liquid autologous concentrated growth factor (CGF) layer 202, which is rich in platelets and growth factors. It is milky white or pale yellow and has a thin, flocculent liquid texture. Its main components include high concentrations of platelets, growth factors, and a small number of white blood cells. It is the core part of CGF and is used for tissue repair and regeneration. The middle layer 202 is further divided into three layers: the upper white part 202-1, the lower red part 202-3, and the middle red-white intersecting part 202-2. The lower layer is red blood cells and a small number of white blood cells 203. It is dark red and has a dense, thick texture. Its main component is red blood cells, with a small number of white blood cells and cell debris. Therefore, it is evident that the centrifuged blood exhibits significant differences in color and texture. Through analysis, the liquid autologous concentrated growth factor (CGF) layer can be accurately identified and extracted. In this embodiment, the portion 202-2 at the interface between the red and white liquid layers is extracted from the liquid autologous platelet aggregate and used as liquid autologous concentrated growth factor for treating the surface of the implant 115. Specifically, venous blood is drawn from the patient using a 4 ml blood collection tube. After processing in the first centrifuge 102, the growth factor-rich liquid, i.e., the liquid autologous concentrated growth factor, is extracted from the 4 ml blood collection tube and stored for later use.

[0021] Next, the liquid autologous concentrated growth factor extractor 103 extracts liquid autologous concentrated growth factor from the liquid autologous platelet aggregate carried in the blood collection tube 114, injects the extracted liquid autologous concentrated growth factor into the liquid autologous concentrated growth factor container 104, and sends the liquid autologous concentrated growth factor container 104 to the second centrifuge 109.

[0022] If the surface of the untreated implant 115 needs to be covered with the patient's autologous concentrated growth factor, the untreated implant 115 is sent to the second centrifuge 109.

[0023] The second centrifuge 109 is used to place the untreated implant 115 into the liquid autologous concentrated growth factor container 104, so that the untreated implant 115 is immersed in the liquid autologous concentrated growth factor. Then, the liquid autologous concentrated growth factor and the untreated implant 115 are centrifuged to obtain an implant with the surface covered with the patient's autologous concentrated growth factor, which is used as the post-treated implant. The post-treated implant is sent to the implant exit mechanism 110 to complete the implant processing. The implant exit mechanism 110 is used to place the post-treated implant into the patient's oral cavity.

[0024] In this embodiment of the application, a controller 111 is also provided in the implant processing machine 100.

[0025] The blood collection tube inlet mechanism 101 or the first centrifuge 102 obtains image data of the blood in the blood collection tube 114 and sends the blood image data to the controller 111. The liquid autologous concentrated growth factor extractor 103 obtains image data of liquid autologous platelet agglomerates and liquid autologous concentrated growth factor, and sends the image data of liquid autologous platelet agglomerates and liquid autologous concentrated growth factor to the controller 111.

[0026] In specific operation, in this embodiment of the application, the above-mentioned blood image data acquisition can be completed in the blood collection tube inlet mechanism 101, the first centrifuge 102, or the liquid autologous concentrated growth factor extractor 103. The blood collection tube inlet mechanism 101, the first centrifuge 102, or the liquid autologous concentrated growth factor extractor 103 can be equipped with a high-definition macro camera and a supplementary light source to ensure that the image data of the blood in the blood collection tube 114 can be clearly captured.

[0027] During the extraction of liquid autologous concentrated growth factor, the first centrifuge 102 sends the image data of the liquid autologous platelet aggregate obtained after centrifugation and settling to the controller 111. The controller 111 performs image analysis on the image data of the liquid autologous platelet aggregate, locates the position 202-2 of the boundary between the red and white liquid in the image, obtains the positioning information, and sends the positioning information to the liquid autologous concentrated growth factor extractor 103. The liquid autologous concentrated growth factor extractor 103 receives the positioning information sent by the controller 111, uses a sterile puncture assembly to puncture the sealing cap of the blood collection tube 114, determines the puncture depth according to the positioning information, and inserts it into the designated position. The negative pressure suction module built into the liquid autologous concentrated growth factor extractor 103 slowly aspirates the liquid autologous concentrated growth factor from the platelet aggregate layer at a preset negative pressure value. The extraction process is monitored in real time to ensure that only the position 202-2 of the boundary between the red and white liquid in the image is extracted.

[0028] The boundary of the liquid self-concentrated growth factor layer near position 202-2, where the red and white liquids meet, is clearly defined and exhibits a color difference from the layers above and below, providing identifiable visual features for image analysis and localization. For details, please refer to... Figure 1The image analysis module of controller 111 forms identifiable visual features based on the color difference between the liquid autologous concentrated growth factor layer and the upper and lower layers, and completes the precise positioning of the interface. Simultaneously, controller 111 converts the positioned interface information into a visual marker and transmits it to the human-machine interface 112. The human-machine interface 112 can intuitively display this information on the high-definition touch screen of implant processing machine 100, allowing medical staff to manually review and confirm the positioning results. During the aspiration of liquid autologous concentrated growth factor by liquid autologous concentrated growth factor extractor 103, the first centrifuge 102 can repeatedly collect images inside the blood collection tube at preset time intervals. Through comparative analysis of consecutive frame images, it identifies and tracks the positional changes of the liquid autologous concentrated growth factor layer interface in real time, and synchronously transmits the real-time aspiration position data to the human-machine interface 112, which dynamically displays the data on the high-definition touch screen of implant processing machine 100, allowing medical staff to make timely manual interventions during the aspiration process based on the displayed data.

[0029] As an optional embodiment of this application, the controller 111 is further configured to obtain the patient's autologous concentrated growth factor quality data based on the blood volume data and the liquid autologous concentrated growth factor volume data, obtain the centrifugation parameter data of the liquid autologous concentrated growth factor and the untreated implant 115 in the second centrifuge 109 based on the patient's autologous concentrated growth factor quality data, and send the centrifugation parameter data of the liquid autologous concentrated growth factor and the untreated implant 115 in the second centrifuge 109 to the second centrifuge 109. Centrifugation of the liquid autologous concentrated growth factor and the untreated implant 115 includes: centrifuging the liquid autologous concentrated growth factor and the untreated implant 115 in the second centrifuge 109 based on the centrifugation parameter data of the liquid autologous concentrated growth factor and the untreated implant 115 in the second centrifuge 109.

[0030] The blood collection tube inlet mechanism 101 or the first centrifuge 102 measures the volume of blood in the blood collection tube 114 and sends the blood volume data to the controller 111. Specifically, the blood collection tube inlet mechanism 101 or the first centrifuge 102 can determine the total volume of blood collected from each patient for commonly used clinical "fixed volume blood collection tubes" (such as 4ml and 9ml specifications, with the precise volume marked at the factory); or it can measure the overall weight through a weight sensor and subtract the weight of the blood collection tube from it. For example, based on the medical standard of blood density of approximately 1.05g / cm³, the weighing result can be converted into volume, such as a weight of 5.04g corresponding to a volume of 4.8ml.

[0031] The liquid autologous growth factor extractor 103 measures the volume of the liquid autologous growth factor extracted from the liquid autologous platelet aggregate and sends the volume data to the controller 111. The liquid autologous growth factor extractor 103 can also use the same measurement method as the blood collection tube inlet mechanism 101 or the first centrifuge 102 to measure the volume of the liquid autologous growth factor, which will not be elaborated further here.

[0032] In this embodiment of the application, the patient's autologous concentrated growth factor quality data is obtained based on the blood volume data and the liquid autologous concentrated growth factor volume data. This includes: inputting the blood volume data and the liquid autologous concentrated growth factor volume data into the autologous concentrated growth factor quality prediction model to obtain the patient's autologous concentrated growth factor quality data output by the autologous concentrated growth factor quality prediction model.

[0033] Based on the patient's autologous concentrated growth factor quality data, centrifugation parameter data of liquid autologous concentrated growth factor and untreated implant 115 in the second centrifuge 109 is obtained, including: inputting the patient's autologous concentrated growth factor quality data into the centrifugation parameter data prediction model, and obtaining the centrifugation parameter data of liquid autologous concentrated growth factor and untreated implant 115 in the second centrifuge 109 output by the centrifugation parameter data prediction model.

[0034] In this embodiment, the autologous concentrated growth factor quality data output by the autologous concentrated growth factor quality prediction model refers to an indicator that reflects the transformation relationship and proportional characteristics between the volume data of autologous concentrated growth factor. For example, the ratio of liquid autologous concentrated growth factor volume to blood volume reflects the content of liquid autologous concentrated growth factor. If its proportion is lower than a preset threshold, the centrifugation time of the second centrifuge 109 needs to be adjusted (e.g., appropriately extended by 1-2 minutes or repeated once) to ensure that the liquid autologous concentrated growth factor adheres more fully to the implant surface, thus compensating for the problem caused by insufficient liquid autologous concentrated growth factor content.

[0035] In this embodiment, the autologous concentrated growth factor quality prediction model and the centrifugation parameter data prediction model are trained in the following manner: The sample volume data of the blood of the sample patient in the sample blood collection tube 114, the sample volume data of the liquid autologous concentrated growth factor extracted from the liquid autologous platelet aggregate of the sample patient, the quality label data of the autologous concentrated growth factor of the sample patient expected based on the blood sample volume data and the sample volume data of the liquid autologous concentrated growth factor, and the centrifugation parameter label data of the liquid autologous concentrated growth factor of the sample patient and the untreated implant 115 of the sample patient in the second centrifuge 109 expected based on the quality label data of the autologous concentrated growth factor.

[0036] The quality label data for autologous concentrated growth factors can be set in conjunction with laboratory test results, and then correlated with the conversion ratio of volume data to form corresponding labels for volume characteristics and quality. The centrifugation parameter label data in the second centrifuge 109 can be set based on clinical validation results. For example, for different samples, the optimal parameters can be determined as labels by comparing the coverage of liquid autologous concentrated growth factors in the implant under different centrifugation parameters.

[0037] The sample volume data of blood and the sample volume data of liquid autologous concentrated growth factor are input into the initial autologous concentrated growth factor quality prediction model to obtain the autologous concentrated growth factor quality prediction data of the sample patients output by the initial autologous concentrated growth factor quality prediction model.

[0038] The autologous concentrated growth factor quality prediction data and autologous concentrated growth factor quality label data are input into a loss function used to evaluate the degree of autologous concentrated growth factor quality prediction loss, and the autologous concentrated growth factor quality prediction loss data between the autologous concentrated growth factor quality prediction data and the autologous concentrated growth factor quality label data are obtained.

[0039] The quality prediction data of autologous concentrated growth factor is input into the initial centrifugation parameter data prediction model to obtain the liquid autologous concentrated growth factor of the sample patient and the centrifugation parameter prediction data of the untreated implant 115 of the sample patient in the second centrifuge 109.

[0040] The centrifugation parameter prediction data and centrifugation parameter label data are input into a loss function used to evaluate the degree of centrifugation parameter prediction loss, and the centrifugation parameter prediction loss data between the centrifugation parameter prediction data and the centrifugation parameter label data is obtained.

[0041] If both the predicted loss data for autologous concentrated growth factor (AGF) quality and the predicted loss data for centrifugation parameters are acceptable loss data, then the initial AGF quality prediction model and the initial centrifugation parameter prediction model are determined to be applicable AGF quality prediction models and centrifugation parameter prediction models, respectively. Otherwise, if at least one of the predicted loss data for autologous concentrated growth factor quality and the predicted loss data for centrifugation parameters are unacceptable loss data, then the model parameters of the initial AGF quality prediction model and the initial centrifugation parameter prediction model are adjusted until both the predicted loss data for autologous concentrated growth factor quality and the predicted loss data for centrifugation parameters obtained from the adjusted AGF quality prediction model and the adjusted centrifugation parameter prediction model are determined to be acceptable loss data. In this case, the adjusted AGF quality prediction model and the adjusted centrifugation parameter prediction model are determined to be applicable AGF quality prediction models and centrifugation parameter prediction models, respectively.

[0042] Therefore, both the autologous concentrated growth factor quality prediction model and the centrifugation parameter data prediction model follow the logic of collaborative training. The output of the former directly determines the input of the latter, and both must simultaneously meet the loss threshold requirement to ensure accurate and reliable prediction results from volume data to quality indicators and then to centrifugation parameters. This prediction mode based on volume data is more quantitative and objective than that based on image data. Furthermore, the centrifugation parameter data prediction model, based on these quantified quality indicators, can further enable personalized treatment for different patients, ensuring that implants in different patients achieve optimal results, providing stable biological support for implant osseointegration, and reducing the risk of postoperative complications such as loosening and infection.

[0043] Based on this, in the embodiments of this application, the patient's autologous concentrated growth factor quality data includes at least one of the following: quality level data representing the quality level of the patient's autologous concentrated growth factor, quality normalized data representing the quality of the patient's autologous concentrated growth factor, and data on the content of liquid autologous concentrated growth factor in the patient's blood in the blood collection tube 114.

[0044] These three types of data are used to quantitatively assess the quality of liquid autologous growth factor concentrate extracted from the patient's blood. Quality grade data is a graded, qualitative quantitative data that divides the content of liquid autologous growth factor concentrate into several distinct levels (e.g., low, medium, and high grades). Quality normalization data is a continuous, quantitative quantitative data, typically a numerical value (e.g., a decimal between 0 and 1, or a fraction between 0 and 100), enabling a more refined and continuous quantification of the quality of the liquid autologous growth factor concentrate. Content data refers to the quantity of liquid autologous growth factor concentrate, representing the total volume of the final extracted liquid autologous growth factor concentrate. Therefore, in this embodiment, when assessing the quality of the produced liquid autologous growth factor concentrate, all three types of data can form the basis for personalized treatment decisions. This allows the implant processing machine 100 to dynamically adjust the most suitable implant surface treatment scheme based on the specific quality of the liquid autologous growth factor concentrate prepared from each patient's blood, thereby achieving stable and efficient treatment results.

[0045] The centrifugation parameter data of liquid autologous concentrated growth factor and surface untreated implant 115 in the second centrifuge 109 includes the centrifugation time data of liquid autologous concentrated growth factor and surface untreated implant 115 in the second centrifuge 109.

[0046] In practical applications, the controller 111 is also used to send a medical data acquisition request message to the medical data server after receiving a blood collection data acquisition instruction for the patient, to obtain the patient's medical data returned by the medical data server, input the patient's medical data into a blood collection data prediction model for predicting blood collection data, obtain the blood collection data output by the blood collection data prediction model representing the amount of blood required to treat the surface of the untreated implant 115, and send the blood collection data output by the blood collection data prediction model to the human-computer interaction device 112. The patient's medical data includes the required implant specifications and the number of implants to be placed.

[0047] The human-computer interface 112 is used to display the blood collection data output by the blood collection data prediction model.

[0048] The blood in blood collection tube 114 is collected based on the blood collection volume data output by the blood collection volume prediction model.

[0049] The implantation needs of different patients vary, and the size and number of implants required for each patient are different. Correspondingly, the amount of blood that needs to be collected in advance before the operation is also different. Therefore, the blood collection stage before the operation needs to make targeted predictions of the amount of blood to be collected based on the individual needs of the patients.

[0050] Specifically, the specifications of implants in clinical practice are currently divided into diameter specifications and length specifications. For example, the diameter specifications of implants may include 3.3 mm, 3.5 mm, 4.1 mm, 4.3 mm, 4.8 mm, etc.; the length specifications of implants may include 8 mm, 10 mm, 11.5 mm, 12 mm, 13 mm, 14 mm, etc.

[0051] There is a specific correlation between the specifications of the implant and the required content of liquid autologous growth factor concentrate. The implant is placed in a container filled with liquid autologous growth factor concentrate and centrifuged twice. Centrifugal force allows the liquid autologous growth factor concentrate to fully penetrate the microporous structure of the implant surface, ensuring complete coverage. The target state after treatment is the formation of a uniform, continuous film of liquid autologous growth factor concentrate on the implant surface. This film must cover the entire area of ​​the implant to be implanted into the bone, and its thickness should be moderate, neither flowing or accumulating, nor exposing any metal surface. The required implant diameter and length determine its surface area; a larger surface area requires a higher content of liquid autologous growth factor concentrate. For multiple large implants, more liquid autologous growth factor concentrate is needed. If necessary, two tubes of blood-derived liquid autologous growth factor concentrate can be used together to achieve sufficient coverage of the implant surface. In practical applications, when using liquid autologous concentrated growth factors to treat the implant surface, the standard implant packaging usually includes a carrier. By holding this carrier, the implant is suspended in the air, ensuring that the bottom and side surfaces of the implant are fully covered. Although the implant surface contains structures such as threads, for the purpose of standardized estimation of its surface area, it can be approximated as a smooth surface.

[0052] Specifically, there is an upper limit to the amount of liquid autologous growth factor (AGF) that can be extracted from a single blood collection tube. Based on clinical experience, the following reference values ​​apply: for a 4 ml blood collection tube, approximately 1 ml of AGF can be extracted from a single tube; for a 9 ml blood collection tube, approximately 2 ml can be extracted. Theoretically, the area that 1 ml of AGF can cover can be estimated by its coverage thickness. This preset coverage thickness can be set based on calculations or estimations that meet coverage conditions (e.g., 0.01-0.1 mm). This is only an estimation parameter used to estimate and predict the required volume of AGF and is not used as a standard or limiting factor for determining the actual thickness of the AGF layer adhering to the implant surface after centrifugation. Based on this reference value, the required AGF content for implant surface treatment of different sizes and numbers of implants can be calculated by matching the implant surface area with the AGF content, and further, the amount of blood to be extracted preoperatively can be determined.

[0053] The following examples illustrate this correspondence.

[0054] In clinical applications, the taper of implants from different brands varies, making the calculation process complex and difficult to standardize. Therefore, to simplify and standardize the estimation of implant surface area, the implant is estimated as an equivalent cylinder, and its surface area can be calculated using the following formula: Formula 1 in, Pi; The diameter of the base is in millimeters. The length of the implant (i.e., the height of the cylinder) is measured in millimeters.

[0055] Based on the above formula, and combined with the diameter of commonly used implants in clinical practice... and length This allows for the estimation of the implant's surface area. For example, for small implants ( Its surface area is approximately 100 square millimeters; while large-sized implants ( Its surface area is approximately 247 square millimeters. Due to the threaded and microporous structures on the implant surface, its actual effective area is larger than the surface area of ​​an equivalent smooth cylinder. Therefore, when clinically matching the content of liquid autologous concentrated growth factor, an area compensation of 20% to 40% can be added to the calculated result to ensure that the implant surface is completely covered. After estimating the amount of liquid autologous concentrated growth factor required for surface treatment of a single implant, the required amount of liquid autologous concentrated growth factor for each implant is cumulatively calculated based on the actual number of implants placed in the patient and the specific specifications of each implant. This yields the total amount of liquid autologous concentrated growth factor required by the patient, serving as a quantitative basis for predicting the total blood volume to be drawn.

[0056] Furthermore, in practice, liquid autologous growth factor cannot be completely used to cover the implant surface, resulting in some loss and increasing the actual amount of liquid autologous growth factor used. For example, for large implants, the maximum amount of liquid autologous growth factor that can be used per implant is approximately 0.2-0.3 ml. This loss is even more pronounced in scenarios where multiple implants (e.g., 12) need to be placed in a single surgery. Therefore, before implantation surgery, it is necessary to estimate the actual amount of liquid autologous growth factor required in advance, taking into account the size and parameters of the implant to be placed and the losses incurred during the actual procedure.

[0057] In clinical blood collection procedures, standardized blood collection is performed using a single blood collection tube as the baseline, avoiding half-tube or other non-full-tube blood collection operations. Correspondingly, the preparation and use of liquid autologous concentrated growth factor are also based on the unit of measurement of liquid autologous concentrated growth factor extracted from a single tube of blood, and the dosage allocation and blood collection volume are determined in accordance with this standardized blood collection rule. Specifically, for one or more small-sized implants, if the estimated required amount of liquid autologous concentrated growth factor is less than 1 ml, blood is still collected in units of 4 ml per tube. The 1 ml of liquid autologous concentrated growth factor extracted from a single tube of blood is used to complete the surface treatment of the implant, meeting the requirement of uniform and continuous coverage of the implant surface. For one or more large-sized implants, if the estimated required amount of liquid autologous concentrated growth factor exceeds 1 ml but is less than 2 ml, blood is still collected in units of two tubes. The 2 ml of liquid autologous concentrated growth factor extracted from two tubes of blood achieves sufficient coverage of the implant surface, avoiding implant damage due to insufficient liquid autologous concentrated growth factor. For patients requiring multiple implants of different sizes, the required amount of liquid autologous growth factor for each implant of the same size is first calculated. Then, the required amount of liquid autologous growth factor for all implants is summed to obtain the total amount of liquid autologous growth factor required by the patient. This determines the number of standardized blood collection tubes to match the patient's needs. In the subsequent secondary centrifugation process of the implants, the total amount of extracted liquid autologous growth factor is allocated to the corresponding implants as needed, based on the actual calculated amount for each implant. This ensures that the surface treatment of each implant can obtain an appropriate amount of liquid autologous growth factor, achieving a uniform coverage effect on all implant surfaces.

[0058] In this embodiment, the blood collection volume is predicted in advance using a blood collection volume prediction model to pre-determine the matching blood collection volume for different patients. On the one hand, predicting in advance the minimum blood collection volume required to extract sufficient liquid autologous concentrated growth factor avoids affecting the final implantation effect due to insufficient blood collection; on the other hand, while meeting the requirements of liquid autologous concentrated growth factor, the blood collection volume is controlled within the patient's tolerance range to avoid safety hazards caused by blind blood collection.

[0059] In this embodiment of the application, the blood collection data prediction model is trained in the following manner: Obtain medical data from sample patients and, based on this medical data, the desired blood collection volume label data for each sample patient.

[0060] The medical data of the sample patients includes the specifications and number of implants required by the sample patients; the blood volume label data is the blood volume data of the sample patients obtained based on the specifications and number of implants required by the sample patients.

[0061] The medical data of the sample patients are input into the initial blood collection volume prediction sub-model to obtain the blood collection volume prediction data for the sample patients output by the initial blood collection volume prediction sub-model.

[0062] The predicted blood volume data and the blood volume label data are input into a loss function used to evaluate the degree of loss in blood volume prediction, and the blood volume prediction loss data between the predicted blood volume data and the blood volume label data is obtained.

[0063] If the predicted blood volume loss data is acceptable, the initial blood volume prediction sub-model is used as the applicable blood volume prediction model. Otherwise, if the predicted blood volume loss data is unacceptable, the model parameters of the initial blood volume prediction sub-model are adjusted until the predicted blood volume loss data obtained from the adjusted blood volume prediction sub-model is acceptable. The adjusted blood volume prediction sub-model is then used as the applicable blood volume prediction model.

[0064] In practice, blood is drawn from different patients based on the blood collection volume prediction model, and the blood collection tube 114 is sent to the first centrifuge 102 for centrifugation. The specific steps are as follows: First, the controller 111 sends the blood collection volume prediction model output for a specific patient to the human-machine interface 112. The human-machine interface 112 can then visually present this data on the high-definition touchscreen display of the implant processor 100. For example, the screen might display "Patient XXX, Implant Specifications: XXX, Number of Implants: XXX, Recommended Blood Collection Volume: 8 ml, Blood Collection Tube Size: 4 ml," allowing medical staff to clearly and intuitively obtain the patient's blood collection volume information. Simultaneously, medical staff can also manually modify the recommended blood collection volume or directly input a custom blood collection volume based on the patient's actual condition, implant specifications and quantity, and clinical experience, improving operational flexibility and clinical adaptability.

[0065] After confirming the final blood volume, the medical staff determines how many tubes of blood need to be drawn from the patient based on the specifications of the corresponding blood collection tube 114, prepares the necessary supplies, and then proceeds with the blood collection. The medical staff verifies the patient's identity using their medical card, confirming that the information matches the patient information displayed on the human-computer interaction device 112, and then selects a suitable blood collection site to begin the process.

[0066] After blood collection, please refer to... Figure 3A Medical staff place one or more blood collection tubes 114, each labeled with patient information, into the blood collection tube inlet mechanism 101 of the implant processor 100, and then transfer them to the first centrifuge 102. Please refer to [reference needed]. Figure 3B The first centrifuge 102 centrifuges one or more blood collection tubes 114 to obtain centrifuged blood collection tubes 114 containing the patient's blood.

[0067] The blood collection volume predicted by the blood collection volume data prediction model is used to collect blood from the patient. This process effectively avoids the human operation error that exists in traditional experience-based blood collection (such as collecting a uniform 4 ml of blood). It ensures that the entire implantation surgery process is supported by objective quantitative data. This is not only an important link to improve the success rate of implantation and reduce the incidence of postoperative complications, but also provides an important data foundation for the automation and efficient operation of the implantation process.

[0068] In this embodiment, the measurement process of blood volume data and liquid autologous concentrated growth factor volume data includes a liquid autologous concentrated growth factor quality prediction stage and a blood collection volume prediction stage. The liquid autologous concentrated growth factor quality prediction stage uses the quality indicators of the liquid autologous concentrated growth factor as a basis, and adaptively adjusts the centrifugation parameters during the centrifugation process between the liquid autologous concentrated growth factor and the implant according to its preset quality requirements. By controlling this centrifugation process, it ensures that the liquid autologous concentrated growth factor fully and stably adheres to the implant surface. The blood collection volume prediction stage, based on the specifications and number of implants to be placed, pre-calculates and predicts the target amount of liquid autologous concentrated growth factor required to cover the implant surface, and then determines the corresponding blood collection volume. The essence of the blood collection volume prediction stage is to predict the target total amount of liquid autologous concentrated growth factor required based on clinical needs, while the essence of the liquid autologous concentrated growth factor quality prediction stage is to determine the corresponding centrifugation parameters based on the target quality requirements. These two stages work together and are executed sequentially to achieve accurate extraction and efficient utilization of the liquid autologous concentrated growth factor.

[0069] like Figure 1 As shown in this embodiment, the implant processing machine 100 further includes a splitter 106. Specifically, before the untreated implant 115 is sent to the second centrifuge 109, the untreated implant 115 is sent to the splitter 106. The splitter 106, upon arrival of the untreated implant 115, sends a splitter instruction request message to the controller 111 to request a splitter instruction, and obtains the splitter instruction issued by the controller 111. If the splitter instruction indicates that the untreated implant 115 is sent to the second centrifuge 109, then the untreated implant 115 is sent to the second centrifuge 109; if the splitter instruction indicates that the untreated implant 115 is sent to the implant outlet mechanism 110, then the untreated implant 115 is sent to the implant outlet mechanism 110.

[0070] Upon receiving a shunt instruction request message, controller 111 determines whether the surface of the untreated implant 115 needs to be covered with the patient's autologous concentrated growth factor. If so, it generates a shunt instruction to instruct the untreated implant 115 to be sent to the second centrifuge 109 and sends the shunt instruction to splitter 106. Otherwise, it generates a shunt instruction to instruct the untreated implant 115 to be sent to the implant outlet mechanism 110 and sends the shunt instruction to splitter 106.

[0071] In this embodiment, during the processing of the implant processor 100, the splitter 106 and the conveying mechanism together constitute an efficient material conveying system, ensuring that the implant and the collected patient blood flow in an orderly manner between each processing stage.

[0072] The splitter 106 integrates a guiding mechanism and sensors. When the implant arrives at the splitter 106, the sensors detect its position and feed the information back to the controller 111. The controller 111 then issues a command based on the judgment result, driving the guiding mechanism to precisely guide the implant along the corresponding delivery path. The guiding mechanism can be driven by a high-precision motor, ensuring the implant enters the target delivery channel accurately and smoothly, laying the foundation for subsequent processing.

[0073] The conveying mechanism employs a combined belt drive and roller drive system. Through the synergistic effect of these two transmission methods, the implant and the blood-carrying medium are ensured to remain stable and precise during transport. Furthermore, the transmission speed can be flexibly adjusted according to the needs of different processing stages, and is uniformly controlled by the controller 111 throughout the entire process, further enhancing the controllability and adaptability of the entire conveying process.

[0074] Furthermore, since there are significant differences in the physiological and bone conditions of different patients, the treatment methods for implants and the parameter settings during implant treatment vary for different patients in this embodiment of the application.

[0075] For each patient, the implant processing machine 100 will obtain and analyze the patient's information in detail before starting work in order to develop a personalized treatment plan.

[0076] Specifically, in this embodiment, to accurately obtain patient information, the implant processor 100 can initiate a data request to the medical data server in advance via the controller 111. For example, it can establish a data connection with the medical data server through a preset interface protocol to obtain the patient's recent examination reports, including oral CBCT (Cone Beam Computer Tomography) image data (used to analyze alveolar bone density, bone thickness, and bone type, such as the classification from Class 1 compact bone to Class 4 cancellous bone). The controller 111 integrates this data into structured information, providing a basis for the formulation of subsequent processing plans.

[0077] The process by which the aforementioned controller 111 initiates data requests to the medical data server, retrieves relevant patient examination reports, and integrates them into structured information is all carried out with the patient's permission and authorization.

[0078] Specifically, for patients with different bone conditions, the controller 111 obtains the patient's bone density data before determining whether the surface of the untreated implant 115 needs to be covered with the patient's autologous concentrated growth factor. The bone density data specifically refers to the bone density grade. Determining whether the surface of the untreated implant 115 needs to be covered with the patient's autologous concentrated growth factor includes: if the patient's bone density grade is 2 or 3, then it is determined that the surface of the untreated implant 115 does not need to be covered with the patient's autologous concentrated growth factor; if the patient's bone density grade is 1 or 4, then it is determined that the surface of the untreated implant 115 needs to be covered with the patient's autologous concentrated growth factor. If it is determined that the surface of the untreated implant needs to be covered with the patient's autologous concentrated growth factor, then it is determined that the patient's blood needs to be collected, and after the patient's blood is collected into a blood collection tube, the blood in the blood collection tube is centrifuged.

[0079] Obtaining a patient's bone density data includes: sending a bone density data acquisition request message to a medical data server to request the patient's bone density data, and obtaining the patient's bone density data returned by the medical data server in response to the bone density data acquisition request message; or, sending a bone medical imaging data acquisition request message to a medical data server to request the patient's bone medical imaging data, obtaining the patient's bone medical imaging data returned by the medical data server in response to the bone medical imaging data acquisition request message, inputting the patient's bone medical imaging data into a bone density data prediction model, and obtaining the patient's bone density data output by the bone density data prediction model.

[0080] Bone mineral density analysis primarily relies on cone-beam computed tomography (CBCT) scans to determine the patient's bone mineral density grade. Specifically, based on imaging examinations and clinical assessment, bone mineral density is classified into four grades (Lekholm and Zarb classifications): Grade 1 (D1): Almost entirely composed of dense bone, with high bone density and limited blood supply. Imagingly, it appears as a bright white with high grayscale values ​​in CBCT images. Grade 2 (D2): Thick, dense bone surrounding porous trabeculae, with relatively high bone density and good blood supply. Imagingly, it appears as a bright white with moderately high grayscale values ​​in CBCT images. Grade 3 (D3): Thin, dense bone surrounding porous trabeculae, with moderate bone density and abundant blood supply. Imagingly, it appears as gray with moderate grayscale values ​​in CBCT images. Grade 4 (D4): Almost entirely composed of porous bone, with low bone density and abundant blood supply. Imaging findings include dark gray or black appearance with low grayscale values ​​on CBCT images. Both very soft and very hard bone conditions are unfavorable for implant growth. When the bone is too soft, bone density is low, and while blood supply is abundant, it cannot initially provide mechanical stability, requiring osteogenesis promotion. Conversely, when the bone is too hard, bone density is high, blood supply is low, and healing is poor later, requiring biological stability for osteogenesis. Therefore, patients with grade 1 and 4 bone conditions require additional implant treatment, while for the general population with good bone conditions (e.g., grade 2 and 3), conventional implants are sufficient, requiring no additional treatment, thus reducing treatment costs and simplifying the procedure.

[0081] As an optional implementation method of this application, implant treatment should not only be judged based on the patient's bone mineral density, but also take into account the actual situation of bone defects. Even if the patient's bone mineral density is in a good state of grade 2 or 3, if there are local bone defects, the implant surface still needs to be covered with the patient's own concentrated growth factor to promote the repair of the bone defect area and enhance the osseointegration effect.

[0082] When the controller 111 determines that the patient's bone density is at grade 2 or 3 (good bone condition), it transmits the result to the human-machine interface 112 in real time. The human-machine interface 112 displays the bone grade, bone density, and other assessment information visually on the high-definition touchscreen of the implant processing machine 100, allowing medical staff to manually review and confirm the information clinically. It also prompts medical staff about any clinical conditions such as bone defects and inquires whether autologous concentrated growth factors need to be applied to the implant surface. Medical staff can confirm or select the appropriate option on the high-definition touchscreen based on the actual situation. The controller 111 automatically executes the corresponding processing procedure based on the final confirmation instruction, ensuring both the objectivity of the implant processing machine 100's assessment and the flexibility and safety of clinical operation.

[0083] In this embodiment of the application, the bone density data prediction model is trained in the following manner: Obtain dental bone medical imaging data of sample patients and dental bone density label data of sample patients expected to be obtained based on dental bone medical imaging data; input dental bone medical imaging data of sample patients into initial dental bone density data prediction model to obtain dental bone density prediction data of sample patients output by initial dental bone density data prediction model; input dental bone density prediction data and dental bone density label data into loss function used to evaluate the degree of dental bone density prediction loss to obtain dental bone density prediction loss data between dental bone density prediction data and dental bone density label data.

[0084] If the bone density prediction loss data is acceptable, the initial bone density prediction model is determined as an applicable bone density prediction model. Otherwise, if the bone density prediction loss data is unacceptable, the model parameters of the initial bone density prediction model are adjusted until the bone density prediction loss data obtained from the adjusted bone density prediction model is acceptable. The adjusted bone density prediction model is then determined as an applicable bone density prediction model.

[0085] In addition, please refer to the embodiments in this application. Figure 1 The implant processing machine 100 also includes a sodium bicarbonate sprayer 107 and an ultraviolet irradiator 108. Before the untreated implants 115 are sent to the second centrifuge 109 by the distributor 106, the distributor 106 also sends the untreated implants 115 to the sodium bicarbonate sprayer 107. The sodium bicarbonate sprayer 107 sprays sodium bicarbonate onto the untreated implants 115 to obtain alkaline-treated implants, which are then sent to the ultraviolet irradiator 108. The ultraviolet irradiator 108 irradiates the alkaline-treated implants with ultraviolet light to obtain ultraviolet-treated implants.

[0086] Based on this, the untreated implant 115 being sent to the second centrifuge 109 by the splitter 106 includes: the implant after ultraviolet irradiation treatment being sent to the second centrifuge 109 by the ultraviolet irradiator 108. Please refer to... Figure 4 The untreated implant 115 is sent to the second centrifuge 109 and immersed in liquid autologous concentrated growth factor 202-2. The liquid autologous concentrated growth factor 202-2 and the untreated implant 115 are centrifuged to obtain an implant with the patient's autologous concentrated growth factor on the surface, which is then used as a surface-treated implant to be implanted in the patient's oral cavity.

[0087] Specifically, as an optional embodiment of this application, when the sodium bicarbonate sprayer 107 sprays sodium bicarbonate onto the untreated implant 115, a 0.5%–1% sterile sodium bicarbonate solution can be used, the spraying pressure controlled at 0.1–0.2 MPa, and the spraying time 30 to 60 seconds. When the ultraviolet irradiator 108 performs ultraviolet irradiation treatment on the alkaline-treated implant, a 254 nm ultraviolet wavelength can be selected, the power density is 10–30 mW / cm², the irradiation distance is 5–10 cm, and the irradiation time is 10 to 15 minutes.

[0088] In the above operations, the sodium bicarbonate sprayer 107 is equipped with a dedicated spray head that can rotate 360 ​​degrees, ensuring that all parts of the implant are cleaned evenly. The sodium bicarbonate solution storage tank adopts a sealed design and is equipped with a liquid level sensor. When the solution level is lower than the set value, the controller 111 will automatically issue a replenishment reminder. At the same time, the cleaning device has a waste liquid recovery system, which can centrally treat the waste liquid after cleaning to avoid environmental pollution. The ultraviolet irradiator 108 uses a high-intensity ultraviolet lamp, and the irradiation intensity can be adjusted according to needs. The irradiation area is a closed space, which can effectively prevent ultraviolet leakage from harming medical personnel. The ultraviolet irradiation can automatically control the opening and closing of the ultraviolet lamp according to the irradiation time set by the controller 111 to ensure the stability of the irradiation effect.

[0089] The jet formed by mixing sodium bicarbonate particles with hot water can thoroughly clean the implant surface, efficiently removing surface impurities and contaminants, providing a clean substrate for subsequent ultraviolet irradiation treatment and laying a good pretreatment foundation. Ultraviolet treatment, as an effective surface modification technology, creates oxygen vacancies on the titanium implant surface, promoting the growth of Ti... 4+ Ions to Ti 3+ Ion conversion leads to the formation of a superhydrophilic surface; simultaneously, this process generates reactive oxygen species, which can inhibit microbial adhesion, achieving bactericidal effects and promoting tissue regeneration. In the embodiments of this application, the combination of sodium bicarbonate spraying and ultraviolet irradiation achieves a synergistic effect in surface treatment. After chemical cleaning removes impurities, ultraviolet irradiation can more fully act on the implant surface, further improving its chemical properties and bioactivity. This combined treatment method is more efficient than a single method, significantly improving the overall performance of the implant, including bioactivity, antibacterial properties, and osseointegration capacity, and has significant clinical application value.

[0090] In this embodiment, when the controller 111 determines, based on the patient's bone density data, that the surface of the untreated implant 115 does not need to be covered with the patient's autologous concentrated growth factor, the controller 111 issues a branching command to send the untreated implant 115 to the implant exit mechanism 110, so that the brancher 106 sends the untreated implant 115 to the implant exit mechanism 110. It is understood that if the controller 111 determines that the surface of the patient's untreated implant 115 does not need to be covered with the patient's autologous concentrated growth factor, then there is no need to draw blood from the patient, and the implant processor 100 does not need to perform the related operation of centrifuging the blood to prepare liquid autologous concentrated growth factor, thereby simplifying the operation process and reducing treatment costs.

[0091] Furthermore, before the splitter 106 delivers the untreated implant 115 to the implant exit mechanism 110, it also delivers the untreated implant 115 to the ultraviolet irradiator 108. The ultraviolet irradiator 108 is used to treat the untreated implant 115 with ultraviolet light, resulting in an ultraviolet-treated implant. Specific details regarding the ultraviolet irradiation process can be found in the preceding descriptions and will not be repeated here.

[0092] Thus, from obtaining patient information to blood collection, centrifugation, and implant processing, a complete personalized implant handling process has been completed. This process is largely automated, requiring minimal human intervention and significantly reducing the probability of human error.

[0093] Corresponding to the implant processing machine provided in the first embodiment of this application, the second embodiment of this application provides an implant processing method, such as... Figure 5 As shown, Figure 5 This is a flowchart illustrating a method for implant processing according to a second embodiment of this application. Since the method embodiment is basically similar to the first embodiment, the description is relatively simple; relevant details can be found in the description of the first embodiment. The method includes the following steps: Step S501: Centrifuge the blood in the blood collection tube to obtain liquid autologous platelet aggregate, wherein the blood in the blood collection tube is the blood of the patient who will have an implant placed in the oral cavity.

[0094] This step involves centrifuging the collected patient blood to obtain centrifuged liquid autologous platelet aggregate.

[0095] Step S502: Extract liquid autologous concentrated growth factor from liquid autologous platelet aggregate, and inject the liquid autologous concentrated growth factor into a liquid autologous concentrated growth factor container.

[0096] This step is used to identify and extract liquid autologous concentrated growth factor from the liquid autologous platelet aggregate obtained after centrifugation. For specific identification and extraction methods, please refer to the corresponding part of the first embodiment.

[0097] Step S503: Place the untreated implant into the liquid autologous concentrated growth factor container so that the untreated implant is immersed in the liquid autologous concentrated growth factor. The untreated implant is an implant that is not covered with the patient's autologous concentrated growth factor.

[0098] Step S504: Centrifuge the liquid autologous concentrated growth factor and the untreated implant to obtain an implant with the patient's autologous concentrated growth factor on the surface, which will be used as a surface-treated implant in the patient's oral cavity.

[0099] This step involves centrifuging the extracted liquid autologous concentrated growth factor and the untreated implant to obtain an implant with the patient's autologous concentrated growth factor on its surface.

[0100] Optionally, it also includes: obtaining the patient's medical data, including the specifications of the implants required by the patient and the number of implants to be implanted; inputting the patient's medical data into a blood collection data prediction model for predicting blood collection data, obtaining blood collection data output by the blood collection data prediction model to represent the amount of blood required for treating the surface of untreated implants; and collecting the patient's blood into blood collection tubes according to the blood collection data output by the blood collection data prediction model.

[0101] For details on the training method of the blood collection data prediction model, please refer to the corresponding section in the first embodiment.

[0102] Optionally, it also includes: determining whether the surface of the untreated implant needs to be covered with the patient's autologous concentrated growth factor; placing the untreated implant into a liquid autologous concentrated growth factor container, including: if it is determined that the surface of the untreated implant needs to be covered with the patient's autologous concentrated growth factor, then placing the untreated implant into the liquid autologous concentrated growth factor container.

[0103] Before determining whether the surface of the untreated implant needs to be coated with the patient's autologous growth factor concentrate, the patient's bone mineral density (BMD) data is obtained, where BMD data refers to the BMD grade. The determination of whether the surface of the untreated implant needs to be coated with the patient's autologous growth factor concentrate includes: if the patient's BMD grade is 2 or 3, then it is determined that the surface of the untreated implant does not need to be coated with the patient's autologous growth factor concentrate; if the patient's BMD grade is 1 or 4, then it is determined that the surface of the untreated implant needs to be coated with the patient's autologous growth factor concentrate. If it is determined that the surface of the untreated implant needs to be coated with the patient's autologous growth factor concentrate, then it is determined that the patient's blood needs to be collected, and after the blood is collected into a blood collection tube, the blood in the blood collection tube is centrifuged.

[0104] Obtaining the patient's bone density data includes: obtaining the patient's bone medical imaging data; inputting the patient's bone medical imaging data into the bone density data prediction model, and obtaining the patient's bone density data output by the bone density data prediction model.

[0105] For details on the training method of the bone density data prediction model, please refer to the corresponding section in the first embodiment.

[0106] Optionally, the method further includes: spraying the untreated implant with sodium bicarbonate before placing it into the liquid autologous concentrated growth factor container to obtain an alkaline-treated implant; subjecting the alkaline-treated implant to ultraviolet irradiation to obtain an ultraviolet-irradiated implant; and placing the untreated implant into the liquid autologous concentrated growth factor container, including: placing the ultraviolet-irradiated implant into the liquid autologous concentrated growth factor container.

[0107] Although this application discloses preferred embodiments as described above, it is not intended to limit this application. Any person skilled in the art can make possible changes and modifications without departing from the spirit and scope of this application. Therefore, the scope of protection of this application should be determined by the scope defined in the claims of this application.

[0108] It should be noted that the user information (including but not limited to user device information, user personal information, etc.) and data (including but not limited to data used for analysis, data stored, data displayed, etc.) involved in this application are all information and data authorized by the user or fully authorized by all parties. Furthermore, the collection, use and processing of the relevant data must comply with the relevant laws, regulations and standards of the relevant countries and regions, and corresponding operation entry points are provided for users to choose to authorize or refuse.

Claims

1. A method for treating implants, characterized in that, include: The blood in the blood collection tube is centrifuged to obtain liquid autologous platelet aggregate, wherein the blood in the blood collection tube is the blood of a patient who is to have an implant placed in the oral cavity; Liquid autologous concentrated growth factor is extracted from the liquid autologous platelet aggregate, and the liquid autologous concentrated growth factor is injected into a liquid autologous concentrated growth factor container. The untreated implant is placed in the liquid autologous concentrated growth factor container so that the untreated implant is immersed in the liquid autologous concentrated growth factor. The untreated implant is an implant that is not covered with the patient's autologous concentrated growth factor. The liquid autologous concentrated growth factor and the untreated implant are centrifuged to obtain an implant with the patient's autologous concentrated growth factor on its surface, which is then used as a surface-treated implant to be implanted into the patient's oral cavity.

2. The implant treatment method according to claim 1, characterized in that, Also includes: Measure the volume of blood in the blood collection tube; Measure the volume data of the liquid autologous concentrated growth factor extracted from the liquid autologous platelet aggregate; Based on the volume data of the blood and the volume data of the liquid autologous concentrated growth factor, the quality data of the patient's autologous concentrated growth factor is obtained. Based on the patient's autologous concentrated growth factor quality data, centrifugation parameter data required for centrifugation of the liquid autologous concentrated growth factor and the untreated implant surface were obtained. The centrifugation process of the liquid autologous concentrated growth factor and the untreated implant includes: centrifuging the liquid autologous concentrated growth factor and the untreated implant according to the centrifugation parameter data.

3. The implant treatment method according to claim 2, characterized in that, The step of obtaining the patient's autologous concentrated growth factor quality data based on the blood volume data and the liquid autologous concentrated growth factor volume data includes: inputting the blood volume data and the liquid autologous concentrated growth factor volume data into an autologous concentrated growth factor quality prediction model to obtain the patient's autologous concentrated growth factor quality data output by the autologous concentrated growth factor quality prediction model. The step of obtaining centrifugation parameter data required for centrifuging the liquid autologous concentrated growth factor and the untreated implant based on the patient's autologous concentrated growth factor quality data includes: inputting the patient's autologous concentrated growth factor quality data into a centrifugation parameter data prediction model, and obtaining the centrifugation parameter data required for centrifuging the liquid autologous concentrated growth factor and the untreated implant output by the centrifugation parameter data prediction model.

4. The implant treatment method according to claim 3, characterized in that, The autologous concentrated growth factor quality prediction model and the centrifugation parameter data prediction model were trained in the following manner: The method obtains sample volume data of blood from a sample blood collection tube, sample volume data of liquid autologous concentrated growth factor extracted from liquid autologous platelet aggregates of the sample patient, quality label data of autologous concentrated growth factor of the sample patient expected based on the sample volume data of blood and the sample volume data of liquid autologous concentrated growth factor, and centrifugation parameter label data required for centrifugation of liquid autologous concentrated growth factor and untreated implant of the sample patient expected based on the quality label data of autologous concentrated growth factor. The sample volume data of the blood and the sample volume data of the liquid autologous concentrated growth factor are input into the initial autologous concentrated growth factor quality prediction model to obtain the autologous concentrated growth factor quality prediction data of the sample patient output by the initial autologous concentrated growth factor quality prediction model. The autologous concentrated growth factor quality prediction data and the autologous concentrated growth factor quality label data are input into a loss function used to evaluate the degree of autologous concentrated growth factor quality prediction loss, so as to obtain the autologous concentrated growth factor quality prediction loss data between the autologous concentrated growth factor quality prediction data and the autologous concentrated growth factor quality label data. The quality prediction data of the autologous concentrated growth factor is input into the initial centrifugation parameter data prediction model to obtain the centrifugation parameter prediction data required for centrifugation of the liquid autologous concentrated growth factor and the untreated implant surface of the sample patient, as output by the initial centrifugation parameter data prediction model. The centrifugation parameter prediction data and the centrifugation parameter label data are input into a loss function used to evaluate the degree of centrifugation parameter prediction loss, thereby obtaining centrifugation parameter prediction loss data between the centrifugation parameter prediction data and the centrifugation parameter label data; If both the predicted loss data for the quality of autologous concentrated growth factor (AGF) and the predicted loss data for centrifugation parameters are acceptable loss data, then the initial AGF quality prediction model is determined as an applicable AGF quality prediction model, and the initial centrifugation parameter prediction model is determined as an applicable centrifugation parameter prediction model. Otherwise, if at least one of the predicted loss data for the quality of autologous concentrated growth factor (AGF) and the predicted loss data for centrifugation parameters is unacceptable loss data, then the model parameters of the initial AGF quality prediction model and the initial centrifugation parameter prediction model are adjusted until both the predicted loss data for the quality of autologous concentrated growth factor (AGF) and the predicted loss data for centrifugation parameters obtained from the adjusted AGF quality prediction model and the adjusted centrifugation parameter prediction model are acceptable loss data. In this case, the adjusted AGF quality prediction model is determined as an applicable AGF quality prediction model, and the adjusted centrifugation parameter prediction model is determined as an applicable centrifugation parameter prediction model.

5. The implant treatment method according to any one of claims 2-4, characterized in that, The patient's autologous concentrated growth factor quality data includes at least one of the following: quality level data representing the quality level of the patient's autologous concentrated growth factor, quality normalized data representing the quality of the patient's autologous concentrated growth factor, and data on the content of liquid autologous concentrated growth factor in the patient's blood in the blood collection tube. The centrifugation parameter data required for centrifuging the liquid autologous concentrated growth factor and the untreated implant includes the centrifugation time data required for centrifuging the liquid autologous concentrated growth factor and the untreated implant.

6. The implant treatment method according to claim 1, characterized in that, Also includes: Obtain the patient's medical data, which includes the specifications of the implants required by the patient and the number of implants to be placed. The patient's medical data is input into a blood collection data prediction model for predicting blood collection data, and the blood collection data output by the blood collection data prediction model is obtained, which represents the amount of blood the patient needs to treat the surface of the untreated implant. Blood from the patient is collected into the blood collection tube according to the blood collection volume data output by the blood collection volume prediction model.

7. The implant treatment method according to claim 6, characterized in that, The blood collection data prediction model was trained in the following manner: Obtain medical data of sample patients and blood collection volume label data for the sample patients expected to be obtained based on the medical data of the sample patients; The medical data of the sample patients are input into the initial blood collection volume data prediction sub-model to obtain the blood collection volume prediction data for the sample patients output by the initial blood collection volume data prediction sub-model. The blood volume prediction data and the blood volume label data are input into a loss function used to evaluate the degree of blood volume prediction loss, and the blood volume prediction loss data between the blood volume prediction data and the blood volume label data is obtained. If the predicted blood volume loss data is acceptable, then the initial blood volume prediction sub-model is used as an applicable blood volume prediction model. Otherwise, if the predicted blood volume loss data is unacceptable, then the model parameters of the initial blood volume prediction sub-model are adjusted until the predicted blood volume loss data obtained from the adjusted blood volume prediction sub-model is acceptable. The adjusted blood volume prediction sub-model is then used as an applicable blood volume prediction model.

8. The implant treatment method according to claim 1, characterized in that, Also includes: Obtain the patient's bone mineral density data, wherein the bone mineral density data refers to the bone mineral density grade; If the patient's bone density grade is 2 or 3, then it is determined that the surface of the untreated implant does not need to be covered with the patient's autologous concentrated growth factor. If the patient's bone density grade is 1 or 4, then the surface of the untreated implant needs to be covered with the patient's autologous concentrated growth factor. If it is determined that the surface of the untreated implant needs to be covered with the patient's autologous concentrated growth factor, then it is determined that the patient's blood needs to be collected, and the blood in the blood collection tube is centrifuged after being collected into the blood collection tube.

9. An implant processing machine, characterized in that, include: The system includes a blood collection tube inlet mechanism, a first centrifuge, a liquid autologous growth factor extractor, a second centrifuge, an implant inlet mechanism, and an implant outlet mechanism. The blood collection tube inlet mechanism is used to place the blood collection tube to be entered into the implant processing machine and to send the blood collection tube to the first centrifuge. The blood collection tube contains the blood of the patient who is to have an implant placed in the oral cavity. The first centrifuge is used to centrifuge the blood in the blood collection tube to obtain liquid autologous platelet aggregate, and the blood collection tube carrying the liquid autologous platelet aggregate is sent to the liquid autologous concentrated growth factor extractor. The liquid autologous concentrated growth factor extractor is used to extract liquid autologous concentrated growth factor from the liquid autologous platelet aggregate carried by the blood collection tube, inject the liquid autologous concentrated growth factor into the liquid autologous concentrated growth factor container, and send the liquid autologous concentrated growth factor container to the second centrifuge. The implant inlet mechanism is used to place implants that are not covered with the patient's autologous concentrated growth factor, and the implants that are not covered with the patient's autologous concentrated growth factor are regarded as untreated implants. The untreated implant is then sent to the second centrifuge; The second centrifuge is used to place the untreated implant into the liquid autologous concentrated growth factor container, so that the untreated implant is immersed in the liquid autologous concentrated growth factor. The liquid autologous concentrated growth factor and the untreated implant are centrifuged to obtain an implant with the patient's autologous concentrated growth factor on its surface, which is then used as a surface-treated implant. The surface-treated implant is then sent to the implant outlet mechanism. The implant exit mechanism is used to place the surface-treated implant to be implanted in the patient's oral cavity.

10. The implant processing machine according to claim 9, characterized in that, It also includes the controller; The blood collection tube inlet mechanism or the first centrifuge is also used to measure the volume data of the blood in the blood collection tube and send the blood volume data to the controller; The liquid autologous concentrated growth factor extractor is also used to measure the volume data of the liquid autologous concentrated growth factor extracted from the liquid autologous platelet aggregate, and send the volume data of the liquid autologous concentrated growth factor to the controller. The controller is used to obtain the patient's autologous concentrated growth factor quality data based on the blood volume data and the liquid autologous concentrated growth factor volume data, obtain the liquid autologous concentrated growth factor and the untreated implant's centrifugation parameter data in the second centrifuge based on the patient's autologous concentrated growth factor quality data, and send the liquid autologous concentrated growth factor and the untreated implant's centrifugation parameter data in the second centrifuge to the second centrifuge. The centrifugation process of the liquid autologous concentrated growth factor and the untreated implant includes: centrifuging the liquid autologous concentrated growth factor and the untreated implant according to the centrifugation parameter data of the liquid autologous concentrated growth factor and the untreated implant in the second centrifuge.

Images